The financing provides near-term runway for phase 3 development of EB613, but substantial dilution is imminent. Monitor for insider buying activity and follow-up filings on warrant exercises. Warrant overhang may pressure the stock until clinical catalysts emerge.
Price Chart
Executive Summary
Entera Bio (ENTX) announced a $10.0 million private placement led by BVF Partners, issuing 7.83 million units at $1.2775 per unit, with each unit including a five-year warrant to buy 1.5 shares at $1.24. If all warrants are exercised, total potential proceeds could reach $24.5 million. The funds will support the phase 3 initiation of EB613 for osteoporosis and general corporate purposes.
Key Financial Metrics
Key Facts
- Private placement of 7,827,789 units at $1.2775 per unit, raising $10.0 million in gross proceeds
- Each unit includes one share (or pre-funded warrant) and a five-year warrant for 1.5 shares at $1.24, representing an 11.7% premium to the March 31 closing price
- Potential additional $14.5 million if all warrants are exercised, bringing total potential proceeds to $24.5 million
- Proceeds to fund phase 3 initiation of EB613 in osteoporosis and general working capital
- BVF-affiliated funds are lead investors in the financing
Financial Impact
$10.0 million raised upfront, up to $24.5 million total with full warrant exercise; significant dilution expected
Risk Factors
- Significant dilution from both new share issuance and potential warrant overhang
- Financing reflects possible difficulty raising capital on favorable terms, given structure and low market cap
- Forward-looking statements dominate press release; no clinical or operational updates provided
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3267368 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | DEF 14A | $2.77 | awaiting T+60 | — | $2.86 (+3.25%) |
Oct 6, 2026 20d ago | 8-K | $2.53 | awaiting T+60 | — | $2.86 (+13.04%) |
Aug 27, 2026 8w ago | Press Release | $3.08 | awaiting T+60 | — | $2.86 (−7.14%) |
Aug 18, 2026 9w ago | 8-K | $2.89 | awaiting T+60 | — | $2.86 (−1.04%) |
Aug 7, 2026 11w ago | Press Release | $3.04 | awaiting T+60 | — | $2.86 (−5.92%) |
Jul 29, 2026 12w ago | Press Release | $3.00 $3.02 | ▲ +0.67% | ▼ −4.06% | $2.86 (−4.67%) |
Jun 16, 2026 18w ago | Press Release | $1.18 $2.79 | ▲ +136.44% | ▲ +135.44% | $2.86 (+142.37%) |
May 28, 2026 21w ago | Press Release | $1.22 $3.23 | ▲ +164.75% | ▲ +163.02% | $2.86 (+134.43%) |
May 18, 2026 23w ago | EFFECT | $1.23 $2.80 | ▲ +127.64% | ▲ +122.79% | $2.86 (+132.52%) |
May 8, 2026 24w ago | S-3 | $1.17 $2.81 | ▲ +140.17% | ▲ +135.78% | $2.86 (+144.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers